רווח נקי למניה (EPS TTM): DBV Technologies SA (DBVT)

DBV Technologies S.A. (DBVT) develops painless Viaskin patches to combat food allergies. This annual net income per share chart visualizes the potential of this segment. Management is persistently overcoming regulatory barriers by implementing safe therapy. However, FDA delays and liquidity shortage risks pose a threat to capital. The current -2.99 metric determines this level of issuer yield.

The technological barrier of DBV Technologies S.A. (DBVT) is based on epicutaneous therapy patents, where commercial success depends directly on regulatory approvals. The annual net income per share trend reflects the actual earnings per share for the year, allowing investors to use this chart to identify a fundamental business slowdown or the risk of overpaying for the asset.